# Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness

- URL: https://theranews.net/blog/2026-04-15-compass-pathways-touts-phase-3-comp360-depression-data-eyes-rolling-nda-and-2026-c5e7fa/
- Published: 2026-04-15
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: thelincolnianonline
- Original report: https://www.thelincolnianonline.com/2026/04/15/compass-pathways-touts-phase-3-comp360-depression-data-eyes-rolling-nda-and-2026-launch-readiness.html
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia. Phase 3 results highlighted rapid and durable antidepressant effects CEO Kabir Nath said the

---
![Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness](/uploads/news-images/compass-pathways-touts-phase-3-comp360-depression-20260415230039.jpeg)

---
*Originally reported by thelincolnianonline. [Read more](https://www.thelincolnianonline.com/2026/04/15/compass-pathways-touts-phase-3-comp360-depression-data-eyes-rolling-nda-and-2026-launch-readiness.html)*

---

*Source: [https://www.thelincolnianonline.com/2026/04/15/compass-pathways-touts-phase-3-comp360-depression-data-eyes-rolling-nda-and-2026-launch-readiness.html](https://www.thelincolnianonline.com/2026/04/15/compass-pathways-touts-phase-3-comp360-depression-data-eyes-rolling-nda-and-2026-launch-readiness.html)*